Quince Therapeutics Inc. (QNCX)
Quince Therapeutics Statistics
Share Statistics
Quince Therapeutics has 44M shares outstanding. The number of shares has increased by 1.82% in one year.
| Shares Outstanding | 44M |
| Shares Change (YoY) | 1.82% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.66M |
| Failed to Deliver (FTD) Shares | 105 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 2.35M, so 5.33% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 5.33% |
| Short % of Float | 7.15% |
| Short Ratio (days to cover) | 2.27 |
Valuation Ratios
The PE ratio is -1.42 and the forward PE ratio is -5.16. Quince Therapeutics's PEG ratio is -0.03.
| PE Ratio | -1.42 |
| Forward PE | -5.16 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 2.68 |
| P/FCF Ratio | -2.52 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Quince Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.49.
| Current Ratio | 6.05 |
| Quick Ratio | 6.05 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | -0.26 |
| Debt / FCF | -0.46 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.58M |
| Employee Count | 36 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -87K |
| Effective Tax Rate | 0.15% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.74, so Quince Therapeutics's price volatility has been higher than the market average.
| Beta | 0.74 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 1.4 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 24.65 |
| Average Volume (20 Days) | 126.95K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -57.28M |
| Net Income | -56.83M |
| EBITDA | -57.28M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 6.21M in cash and 14.81M in debt, giving a net cash position of -8.6M.
| Cash & Cash Equivalents | 6.21M |
| Total Debt | 14.81M |
| Net Cash | -8.6M |
| Retained Earnings | -376.47M |
| Total Assets | 114.48M |
| Working Capital | 36.76M |
Cash Flow
In the last 12 months, operating cash flow was -31.9M and capital expenditures -257K, giving a free cash flow of -32.16M.
| Operating Cash Flow | -31.9M |
| Capital Expenditures | -257K |
| Free Cash Flow | -32.16M |
| FCF Per Share | -0.74 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for QNCX is $9.5, which is 850% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 850% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -4.88 |
| Piotroski F-Score | 3 |